223 research outputs found
Growth Inhibition and Metabolite Pool Levels in Plant Tissues Fed d-Glucosamine and d-Galactose
Comparing the Acute Effects of Intermittent and Continuous Whole-Body Vibration Exposure on Neuromuscular and Functional Measures in Sarcopenia and Nonsarcopenic Elderly Women
This investigation examined the acute effects of continuous whole-body vibration (CWBV) and intermittent whole-body vibration (IWBV) on neuromuscular and functional measures in women with sarcopenia and nonsarcopenic women. Continuous whole-body vibration was one 6-minute exposure, while IWBV consisted of six 60-second exposures to rest intervals (30 Hz, 2-4 mm amplitude). Factorial analyses revealed group × exposure × time interactions for jump height (JH; F = 10.8, P = .002), grip strength (GS; F = 15.5, P < .001), timed up and go test (F = 11.7, P = .002), and sit and reach test (S&R; F = 9.7, P = .004). Both JH and GS significantly improved post-WBV in women with sarcopenia (P < .001), with post-IWBV significantly greater (P < .001) than post-CWBV. Timed up and go test and S&R significantly improved post-IWBV in both the groups (P < .001) with post-IWBV significantly better than post-CWBV (P < .001). Bench press power at 20% one repetition maximum (1RM) revealed an exposure × time interaction (F = 4.6, P = .04) illuminating that IWBV significantly improved muscular power (P < .001). Bench press power at 40% 1RM revealed group × exposure (F = 6.4, P = .016) and exposure × time interactions (F = 5.8, P = .022). Individuals with sarcopenia significantly increased power output (P < .001) post-IWBV which was significantly greater than post-CWBV (P = .037). Bench press power at 60% 1RM revealed an exposure × time interaction (F = 8.6, P = .006), indicating that power was significantly improved post-IWBV (P = .027) and decreased post-CWBV. Berg Balance scale revealed a time main effect (F = 6.64, P = .015), and pain discomfort was significantly lower post-IWBV. These data indicate IWBV may provide a more efficacious exposure pattern in older women when compared to CWBV.The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Article processing charges funded in part by University of Oklahoma Libraries.YesTwo expert reviewers using single-blind process (reviewers' names and information is withheld from the authors). Established Ethics Policy with regards to who can review someone's work. The authors may nominate reviewers but the Editorial Board makes the final decision
Muscle Performance Changes with Age in Active Women
The purpose of this study was to examine age-related differences in muscle performance in women divided into young (YW, 20–39 years, n = 29) middle-aged (MAW, 40–59 years, n = 33), and older (OW, ≥60 years, n = 40) age groups. Methods: Hand grip strength, vertical jump performance, and knee extensor (KE) strength (0 deg/s, 60 deg/s, and 240 deg/s), speed of movement (SoM; at 1 Nm, 20%, 40%, and 60% isometric strength), and endurance (30-repetition test at 60 degs/s and 240 deg/s) were assessed. Computed tomography-acquired muscle cross-sectional area (mCSA) was measured and included to determine specific strength (KE strength/mCSA). Results: Hand grip strength was similar across groups, while jump performance declined with age (YW and MAW \u3e OW, p \u3c 0.001). KE strength declined significantly with age (all conditions p \u3c 0.01), while specific strength was similar across groups. SoM was significantly higher for YW and MAW compared to OW (both p \u3c 0.01). An age × velocity interaction revealed YW KE endurance was similar between conditions, whereas MAW and OW displayed significantly better endurance during the 60 deg/s condition. OW displayed impaired KE endurance at 240 deg/s (vs. YW and MAW, p \u3c 0.01) but improved at 60 deg/s (vs. YW, p \u3c 0.01). Dynamic torque decline increased with age (YW \u3c OW, p = 0.03) and was associated with intramuscular adipose tissue (r = 0.21, p = 0.04). Conclusions: Performance declines were most evident among OW, but few performance deficits had emerged in MAW. Interestingly, strength declines disappeared after normalizing to mCSA and endurance appears to be velocity-dependent
Monitoring External Training Loads and Neuromuscular Performance for Division I Basketball Players over the Preseason
Limited research has paralleled concomitant changes in external training load (eTL) and countermovement jump (CMJ) performance. Therefore, this investigation characterized eTL and CMJ performance changes across preseason training in Division 1 male collegiate basketball athletes, while examining the influence of position (Guard vs. Forward/Center) and scholarship status (Scholarship = S vs. Walk-on = WO). During 22 practices, eTL was monitored in 14 male athletes, with weekly CMJs performed to quantify neuromuscular performance (Jump Height [JH], Flight Time:Contraction Time [FT:CT], Reactive Strength Index Modified [RSIMod ]). PlayerLoad per minute was significantly higher during W1 and W2 (5.4 ± 1.3au and 5.3 ± 1.2au, respectively; p < 0.05) compared to subsequent weeks, but no additional differences in eTL parameters across time were observed. Scholarship athletes displayed greater PlayerLoad (S = 777.1 ± 35.6, WO = 530.1 ± 56.20; Inertial Movement Analysis (IMA) IMA_High (S = 70.9 ± 15.2, WO = 41.3 ± 15.2); IMA_Medium (S = 159.9 ± 30.7, WO = 92.7 ± 30.6); and IMA_Low (S = 700.6 ± 105.1, WO = 405 ± 105.0;) (p < 0.05), with no observed differences in eTL by position. Moderate decreases in FT:CT and RSIMod paralleled increased eTL. Significant increases in practice intensity (W1 and W2) did not impact CMJ performance, suggesting athletes could cope with the prescribed training loads. However, moderate perturbations in FT:CT and RSIMod paralleled the weeks with intensified training. Cumulatively, scholarship status appears to influence eTL while player position does not.The authors would like to thank Mr. Brady Brown and Mr. Keldon Peak for their assistance with this project. Additionally, the authors thank the Basketball Programs at the University of Oklahoma for their continued support of research directed at enhancing athlete performance, while also improving overall student-athlete welfare. Finally, the authors would also like to thank all of the student-athletes that graciously volunteered their time to enroll and participate in this study. The experiments comply with the current laws of the country in which they were performed. The authors have no conflict of interest to declare.
Open Access fees paid for in whole or in part by the University of Oklahoma Libraries.Ye
Aerobic Exercise Training Reduces Cannabis Craving and Use in Non-Treatment Seeking Cannabis-Dependent Adults
Cannabis dependence is a significant public health problem. Because there are no approved medications for this condition, treatment must rely on behavioral approaches empirically complemented by such lifestyle change as exercise.To examine the effects of moderate aerobic exercise on cannabis craving and use in cannabis dependent adults under normal living conditions.Participants attended 10 supervised 30-min treadmill exercise sessions standardized using heart rate (HR) monitoring (60-70% HR reserve) over 2 weeks. Exercise sessions were conducted by exercise physiologists under medical oversight.Sedentary or minimally active non-treatment seeking cannabis-dependent adults (n = 12, age 25±3 years, 8 females) met criteria for primary cannabis dependence using the Substance Abuse module of the Structured Clinical Interview for DSM-IV (SCID).Self-reported drug use was assessed for 1-week before, during, and 2-weeks after the study. Participants viewed visual cannabis cues before and after exercise in conjunction with assessment of subjective cannabis craving using the Marijuana Craving Questionnaire (MCQ-SF).Daily cannabis use within the run-in period was 5.9 joints per day (SD = 3.1, range 1.8-10.9). Average cannabis use levels within the exercise (2.8 joints, SD = 1.6, range 0.9-5.4) and follow-up (4.1 joints, SD = 2.5, range 1.1-9.5) periods were lower than during the run-in period (both P<.005). Average MCQ factor scores for the pre- and post-exercise craving assessments were reduced for compulsivity (P = .006), emotionality (P = .002), expectancy (P = .002), and purposefulness (P = .002).The findings of this pilot study warrant larger, adequately powered controlled trials to test the efficacy of prescribed moderate aerobic exercise as a component of cannabis dependence treatment. The neurobiological mechanisms that account for these beneficial effects on cannabis use may lead to understanding of the physical and emotional underpinnings of cannabis dependence and recovery from this disorder.ClinicalTrials.gov NCT00838448]
Acute and Chronic Effects of Whole-Body Vibration on Balance, Postural Stability, and Mobility in Women With Multiple Sclerosis
The acute and chronic effects of whole-body vibration (WBV) on balance, postural stability, and mobility were evaluated in 21 women with relapsing-remitting multiple sclerosis (MS) randomly assigned to control (n = 9) or experimental (n = 12) groups. To assess acute responses, outcome variables were assessed before and immediately after a session of WBV (five 30-second bouts of vibration; frequency 30 Hz; amplitude 3 mm; 1-minute rest intervals) during their first visit (week 1) using field (Timed-Up and Go; 500-m walk; Berg Balance Scale) and laboratory tests (NeuroCom Balance Master and EquiTest System—Sensory Organization Test, Adaptation Test, Limits of Stability, Modified Clinical Test for Sensory Integration of Balance, Unilateral Stance, Tandem Walk, Step/Quick Turn). Acute responses were also measured after their fifth visit for only the Adaptation and Sensory Organization tests. For the chronic responses, participants were exposed to the WBV protocol once a week, for a total of 5 weeks, and then at week 5, were reassessed with the Adaptation and the Sensory Organization tests. Neither acute nor chronic exposure to the WBV protocols used in this study resulted in significant improvements (P > .05) in balance, postural stability, or mobility as assessed by either field or laboratory tests. However, based on promising results from other studies that have used WBV with other clinical populations, either alone or in conjunction with exercise, additional studies that increase the dose of vibration exposure, both acutely and chronically, should be conducted in patients with MS.Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.Ye
Neuropsychological function in patients with a single gene mutation associated with autosomal dominant nocturnal frontal lobe epilepsy
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a nonlesional condition associated with mutation of the gene coding for the α4 nicotinic acetylcholine receptor (nAChR). The nAChR modulates aspects of memory and attention. We examined the neuropsychological phenotype of ADNFLE, with a particular emphasis on understanding the impact on frontal lobe functions. We used standard clinical tests as well as focused measures of frontal lobe function in a well-defined group of patients with ADNFLE. Their performance was compared with that of a group of age-, sex-, and education-matched control participants. Patients with ADNFLE showed impairments on tasks requiring cognitive flexibility against a background of well-preserved intellectual abilities. In accord with existing research, verbal memory impairments were identified in the patient group; the level of impairment on these tasks correlated with disease-related factors. In our study of ADNFLE associated with one mutation, cognitive flexibility appears to be the core cognitive deficit
Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users
and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis user
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
<p>Abstract</p> <p>Background</p> <p>Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral psychiatric disorder that afflicts children, with a reported prevalence of 2.4% to 19.8% worldwide. Stimulants (methylphenidate [MPH] and amphetamine) are considered first-line ADHD pharmacotherapy. MPH is a catecholamine reuptake inhibitor, whereas amphetamines have additional presynaptic activity. Although MPH and amphetamine can effectively manage ADHD symptoms in most pediatric patients, many still fail to respond optimally to either. After administration, the prodrug stimulant lisdexamfetamine dimesylate (LDX) is converted to l-lysine and therapeutically active d-amphetamine in the blood. The objective of this study was to evaluate the clinical efficacy of LDX in children with ADHD who remained symptomatic (ie, nonremitters; ADHD Rating Scale IV [ADHD-RS-IV] total score > 18) on MPH therapy prior to enrollment in a 4-week placebo-controlled LDX trial, compared with the overall population.</p> <p>Methods</p> <p>In this post hoc analysis of data from a multicenter, randomized, double-blind, forced-dose titration study, we evaluated the clinical efficacy of LDX in children aged 6-12 years with and without prior MPH treatment at screening. ADHD symptoms were assessed using the ADHD-RS-IV scale, Conners' Parent Rating Scale-Revised short form (CPRS-R), and Clinical Global Impressions-Improvement scale, at screening, baseline, and endpoint. ADHD-RS-IV total and CPRS-R ADHD Index scores were summarized as mean (SD). Clinical response for the subgroup analysis was defined as a ≥ 30% reduction from baseline in ADHD-RS-IV score and a CGI-I score of 1 or 2. Dunnett test was used to compare change from baseline in all groups. Number needed to treat to achieve one clinical responder or one symptomatic remitter was calculated as the reciprocal of the difference in their proportions on active treatment and placebo at endpoint.</p> <p>Results</p> <p>Of 290 randomized participants enrolled, 28 received MPH therapy at screening, of which 26 remained symptomatic (ADHD-RS-IV > 18). ADHD-RS-IV total scores, changes from baseline, clinical responsiveness, and rates of symptomatic remission in this subgroup were comparable to the overall population. The safety and tolerability profiles for LDX were comparable to other stimulants currently available.</p> <p>Conclusion</p> <p>In this analysis, children with significant clinical ADHD symptoms despite MPH treatment improved during treatment with LDX and experienced similar improvements in their symptoms as the overall study population.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00556296">NCT00556296</a></p
Differential Pharmacological Actions of Methadone and Buprenorphine in Human Embryonic Kidney 293 Cells Coexpressing Human μ-Opioid and Opioid Receptor-Like 1 Receptors
Methadone and buprenorphine are used in maintenance therapy for heroin addicts. In this study, we compared their effects on adenylate cyclase (AC) activity in human embryonic kidney (HEK) 293 cells stably overexpressing human μ-opioid receptor (MOR) and nociceptin/opioid receptor-like 1 receptor (ORL1) simultaneously. After acute exposure, methadone inhibited AC activity; however, buprenorphine induced compromised AC inhibition. When naloxone was introduced after 30 min incubation with methadone, the AC activity was enhanced. This was not observed in the case of buprenorphine. Enhancement of the AC activity was more significant when the incubation lasted for 4 h, and prolonged exposure to buprenorphine elevated the AC activity as well. The removal of methadone and buprenorphine by washing also obtained similar AC superactivation as that revealed by naloxone challenge. The study demonstrated that methadone and buprenorphine exert initially different yet eventually convergent adaptive changes of AC activity in cells coexpressing human MOR and ORL1 receptors
- …